 The study group consists of patients with potentially curative R0 resectable EC T2-T4aN0M0T1-T4aN1-3M0. These patients should be eligible for neo-adjuvant chemo-radiotherapy CRT including; performanceWHO 2; age 18 yrs; hematology, electrolytes, liver and renal tests within normal range; no prior radio- or chemotherapy that would influence treatment for EC; no other malignancies except basal cell carcinoma of the skin and carcinoma in situ, no active infect at the time of imaging, written informed consent. 